Exonate has successfully fundraised £1.5 million to accelerate development of its lead product – an eye drop treatment for retinal neovascular diseases. More: Exonate fundraises £1.5 million Source: News
read moreBringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases. More: Sanofi and MyoKardia end heart disease drug collaboration Source: News
read moreNHS England is urging patients to cancel appointments rather than just not show up, after news emerged that more than 15 million general practice appointments are being wasted each year because patients do not turn up and fail to warn
read moreIt’s a new year, and many top pharma companies are taking the opportunity to raise prices for their big sellers. As the industry has in the past, several drugmakers opted to raise prices to ring in 2019, with Allergan leading
read moreKey oncology wins helped drive Pfizer and Merck to the top of the Dow in 2018, which could very well lead investors to assume life sciences will be a safe place to park their money this year. Not so fast,
read morePortola will finally see the commercial release of its universal bleeding reversal agent Andexxa, a milestone not only for the biotech but also for Pfizer and Bristol-Myers Squibb, as well as Bayer and Johnson & Johnson, whose blood thinners rely on
read more© 1994 - 2026 B.M. Pharmaceuticals